Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Payables (2016 - 2025)

Historic Payables for Traws Pharma (TRAW) over the last 14 years, with Q3 2025 value amounting to $5.1 million.

  • Traws Pharma's Payables fell 670.69% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 670.69%. This contributed to the annual value of $8.2 million for FY2024, which is 4568.43% up from last year.
  • Traws Pharma's Payables amounted to $5.1 million in Q3 2025, which was down 670.69% from $4.8 million recorded in Q2 2025.
  • Traws Pharma's 5-year Payables high stood at $8.2 million for Q4 2024, and its period low was $2.8 million during Q4 2021.
  • Moreover, its 5-year median value for Payables was $4.9 million (2023), whereas its average is $5.0 million.
  • In the last 5 years, Traws Pharma's Payables crashed by 4295.47% in 2021 and then surged by 6886.45% in 2023.
  • Quarter analysis of 5 years shows Traws Pharma's Payables stood at $2.8 million in 2021, then surged by 40.01% to $3.9 million in 2022, then surged by 45.57% to $5.6 million in 2023, then surged by 45.68% to $8.2 million in 2024, then tumbled by 37.64% to $5.1 million in 2025.
  • Its Payables was $5.1 million in Q3 2025, compared to $4.8 million in Q2 2025 and $7.7 million in Q1 2025.